alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 75, Number 40 (Tuesday, March 2, 2010)]
[Notices]
[Page 9428]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4272]


-----------------------------------------------------------------------

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[LLNV952000 L14200000.BJ0000 241A; 10-08807; MO<greek-i> 4500012336; 
TAS: 14X1109]


Filing of Plats of Survey; Nevada

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The purpose of this notice is to inform the public and 
interested State and local government officials of the filing of Plats 
of Survey in Nevada.

DATES: Effective Dates: Filing is effective at 10 a.m. on the dates 
indicated below.

FOR FURTHER INFORMATION CONTACT: David D. Morlan, Chief, Branch of 
Geographic Sciences, Bureau of Land Management (BLM), Nevada State 
Office, 1340 Financial Blvd., P.O. Box 12000, Reno, Nevada 89520, 775-
861-6541.

SUPPLEMENTARY INFORMATION:
    1. The Plat of Survey of the following described lands will be 
officially filed at the Nevada State Office, Reno, Nevada, on the first 
business day after thirty (30) days from the publication of this 
notice:

    The plat, representing the survey of a portion of the south 
boundary and a portion of the subdivisional lines of Township 5 
North, Range 57 East, Mount Diablo Meridian, Nevada, under Group No. 
870, was accepted February 16, 2010.

This survey was executed to meet certain administrative needs of the 
U.S. Forest Service.

    2. Subject to valid existing rights, the provisions of existing 
withdrawals and classifications, the requirements of applicable laws, 
and other segregations of record, these lands are open to application, 
petition, and disposal, including application under the mineral leasing 
laws. All such valid applications received on or before the official 
filing of the Plat of Survey described in paragraph 1, shall be 
considered as simultaneously filed at that time. Applications received 
thereafter shall be considered in order of filing.
    3. The above-listed survey is now the basic record for describing 
the lands for all authorized purposes. This survey has been placed in 
the open files in the BLM Nevada State Office and is available to the 
public as a matter of information. Copies of the survey and related 
field notes may be furnished to the public upon payment of the 
appropriate fees.

    Dated: February 23, 2010.
David D. Morlan,
Chief Cadastral Surveyor, Nevada.
[FR Doc. 2010-4272 Filed 3-1-10; 8:45 am]
BILLING CODE 4310-HC-P
## SUPREME COURT OF THE STATE OF NEW YORK 

## Appellate Division, Fourth Judicial Department

210 KA 12-01242 PRESENT: SMITH, J.P., FAHEY, CARNI, SCONIERS, AND VALENTINO, JJ.

THE PEOPLE OF THE STATE OF NEW YORK, RESPONDENT,

V MEMORANDUM AND ORDER

MARCO A.C., DEFENDANT-APPELLANT.

D.J. & J.A. CIRANDO, ESQS., SYRACUSE (BRADLEY E. KEEM OF COUNSEL), FOR DEFENDANT-APPELLANT.
JOSEPH V. CARDONE, DISTRICT ATTORNEY, ALBION (KATHERINE BOGAN OF COUNSEL), FOR RESPONDENT.

Appeal from an adjudication of the Orleans County Court (James P. Punch, J.), rendered April 16, 2012. Defendant was adjudicated a youthful offender upon his plea of guilty of attempted burglary in the second degree.
It is hereby ORDERED that the adjudication so appealed from is unanimously affirmed.
Memorandum: Defendant appeals from a youthful offender adjudication convicting him, upon his plea of guilty, of attempted burglary in the second degree (Penal Law §§ 110.00, 140.25 [2]). Defendant’s contention regarding the voluntariness of his plea is not preserved for our review because he did not move to withdraw his plea or to vacate the adjudication on that ground ( see People v Rosado , 70 AD3d 1315, 1315-1316, lv denied 14 NY3d 892). Contrary to defendant’s contention, this case does not fall within the rare exception to the preservation requirement because nothing in the plea allocution calls into question the voluntariness of the plea or casts “significant doubt” upon his guilt ( People v Lopez , 71 NY2d 662, 666; see People v Cubi , 104 AD3d 1225, 1226, lv denied 21 NY3d 1003).
Defendant failed to preserve for our review his contention that County Court erred in ordering restitution without conducting a hearing ( see People v Robinson , 112 AD3d 1349, 1350; People v Baker , 57 AD3d 1500, 1500), and we decline to exercise our power to review that contention as a matter of discretion in the interest of justice ( see CPL 470.15 [3] [c]). To the extent that defendant’s contention that he was denied effective assistance of counsel survives his plea of guilty ( see People v Robinson , 39 AD3d 1266, 1267, lv denied 9 NY3d 869), we reject that contention. The record establishes that defendant received “an advantageous plea and nothing in the record casts doubt on the apparent effectiveness of counsel” ( People v Ford ,-2- 210 KA 12-01242
86 NY2d 397, 404).

Entered: March 21, 2014 Frances E. Cafarell Clerk of the Court
<PAGE>   1
THE LOEWEN GROUP INC
--------------------------------------------------------------------------------
(NYSE, TSE, ME: LWN)                                            NEWS


Investor contact:
Paul Wagler, Senior Vice President
and Chief Financial Officer
The Loewen Group Inc.
(604) 299-9321

                              FOR IMMEDIATE RELEASE


               LOEWEN GROUP EXPECTS LOWER SECOND QUARTER EARNINGS

VANCOUVER, BC, July 22, 1998 _ The Loewen Group announced today that, based on
preliminary earnings estimates, its second quarter 1998 earnings will be
significantly below First Call consensus earnings estimates of $0.31 per share.
The short fall primarily relates to lower pre-need cemetery sales, lower volumes
in funeral homes, adjustments to cemetery accounts receivable and to one-time
unexpected internal costs resulting from the previously announced consolidation
of the Company's Philadelphia, Pennsylvania office, staff reductions and the
transfer of management functions into the Vancouver Head office.

Chairman and C.E.O. Ray Loewen said, "We are extremely disappointed by the
negative surprises encountered in the consolidation of our Philadelphia office.
We are performing a comprehensive review of strategic alternatives available to
the Company with the objective of maximising shareholder value."

Paul Wagler, the Company's Senior Vice President and Chief Financial Officer
stated that "Second quarter results will be announced in early August pending a
thorough analysis and review of preliminary results."


                                    - more -


<PAGE>   2
                                      - 2 -


The Loewen Group Inc. is the second largest funeral home and cemetery operator
in North America. The company employs approximately 16,000 people and owns or
operates more than 1,100 funeral homes and over 500 cemeteries in the United
States, Canada and the United Kingdom. Over 90 per cent of the company's revenue
is derived from the United States.

Note: Certain of the statements contained in this press release, including, but
not limited to, information regarding the future economic performance and
financial condition of the company, the plans and objectives of the company's
management, and the company's assumptions regarding such performance and plans,
are forwardlooking in nature. Additional information concerning important
factors that could cause actual results to differ from the forwardlooking
information contained in this release is included in the company's publicly
filed quarterly and annual reports.


                                       ###
p. 1 of 1

From: Hulse, David G. [ mailto:David.Hulse@alcoa.com ] Sent: Friday, January 03, 2014 6:12 PM To: Putney, David Cc: Palazzolo, Michael A. Subject: FW: Revised Files for Alcoa Inc. - Wenatch ee Works

Here are the files that I submitted previously. I did
notice that the stack diameters for the roof vents are meaningless, since those don't have a "diameter". My understanding was that there is a different method employed in modeling those sources, and that a diameter was not needed. If you need dimensions (Length and width o f the roof opening), please let me know, and I will get t hem to you. Other than that, everything looks correct.

Dave

____________________________________________ From: Hulse, David G. Sent: Monday, January 17, 2011 1:53 PM

To: Boyd.Rochelle@EPA.gov Subject: Revised Files for Alcoa Inc. - Wenatchee W orks

Attached, please find the revised kmz, ReleasePoint , and CategoryHAPs files for the Alcoa Inc. - Wenatchee W orks facility (NEI42328).

The kmz file includes both the emission points and the property boundary.

We used the fugitive (area) source approach to repr esent
the Potline Roof Vents and the Anode Bake Oven Roof Vents. Where we believe that the point should be deleted, the cell
is shaded red. The cells not shaded in red matched MACT
emissions sources and the coordinates were confirme d.

Please contact me if you have any questions.

David Hulse
**EXHIBIT
      32.2**




**CERTIFICATION
      PURSUANT TO**


**18
      U.S.C. SECTION 1350**


**AS
      ADOPTED PURSUANT TO**


**SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002**




In
      connection with the Quarterly Report of Central Wireless, Inc. (the “Company”)
      on Form 10-QSB for the quarter ended June 30, 2006 as filed with the Securities
      and Exchange Commission on the date hereof (the “Report”), the undersigned, in
      the capacities and on the dates indicated below, hereby certifies pursuant
      to 18
      U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
      Act of 2002, that to his knowledge:




1.
      The
      Report fully complies with the requirements of Section 13(a) or 15(d) of the
      Securities Exchange Act of 1934; and




2.
      The
      information contained in the Report fairly presents, in all material respects,
      the financial condition and results of operation of the Company.


Date:
                  January 23, 2007
            By:
            /s/ *Kenneth
              W. Brand*Kenneth
                  W. Brand
                Acting
                  Principal Financial Officer




A
      signed
      original of this written statement required by Section 906, or other document
      authentications, acknowledging, or otherwise adopting the signature that appears
      in typed form within the electronic version of this written statement required
      by Section 906, has been provided to Central Wireless, Inc. and will be retained
      by Central Wireless, Inc. and furnished to the Securities and Exchange
      Commission or its staff upon request.
§ 310.543 Drug products containing active ingredients offered over-the-counter (OTC) for human use in exocrine pancreatic insufficiency. ( a ) Hemicellulase, pancreatin, and pancrelipase have been present as ingredients in exocrine pancreatic insufficiency drug products. Pancreatin and pancrelipase are composed of enzymes: amylase, trypsin (protease), and lipase. Significant differences have been shown in the bioavailability of marketed exocrine pancreatic insufficiency drug products produced by different manufacturers. These differences raise a potential for serious risk to patients using these drug products. The bioavailability of pancreatic enzymes is dependent on the process used to manufacture the drug products. Information on this process is not included in an OTC drug monograph. Therefore, the safe and effective use of these enzymes for treating exocrine pancreatic insufficiency cannot be regulated adequately by an OTC drug monograph. Information on the product's formulation, manufacture, quality control procedures, and final formulation effectiveness testing are necessary in an approved application to ensure that a company has the ability to manufacture a proper bioactive formulation. In addition, continuous physician monitoring of patients who take these drug products is a collateral measure necessary to the safe and effective use of these enzymes, causing such products to be available by prescription only.
( b ) Any drug product that is labeled, represented, or promoted for OTC use in the treatment of exocrine pancreatic insufficiency is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the act), for which an approved application under section 505 of the act and part 314 of this chapter is required for marketing. In the absence of an approved application, such product is also misbranded under section 502 of the act.
( c ) Clinical investigations designed to obtain evidence that any drug product labeled, represented, or promoted for OTC use in the treatment of exocrine pancreatic insufficiency is safe and effective for the purpose intended must comply with the requirements and procedures governing the use of investigational new drugs set forth in part 312 of this chapter.
( d ) After May 7, 1991, any such OTC drug product that contains hemicellulase initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.
( e ) After October 24, 1995, any such OTC drug product that contains pancreatin or pancrelipase initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.
[60 FR 20165, Apr. 24, 1995]
**Exhibit 23.2**

**CONSENT OF ERNST & YOUNGLLP, INDEPENDENT AUDITORS**

 

        Weconsent to the incorporation by reference in the Registration Statement (Form S–8No. 33–98720) pertaining to the 1995 Stock Option Plan of Mackie DesignsInc. of our report dated February 26, 1999 with respect to the consolidatedfinancial statements and schedule of Mackie Designs Inc. for the year endedDecmeber 31, 1998 included in the Annual Report (Form 10-K) for the year endedDecember 31, 2000.

 
|   | Ernst  & Young LLP |
|--------|------------------------|
FORM 10-Q

Securities and Exchange Commission

Washington, D.C.  20549

(Mark One)

[**X**]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended:  **June 30, 2003**
[   ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE 

SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________.

Commission File No. 0-22372.
**GRAND TOYS INTERNATIONAL, INC.**
(Exact Name of Registrant as Specified in its Charter)	
**Nevada                                         		       **98-0163743                                                   
(State or other jurisdiction of			      (I.R.S. Employer

incorporation or organization	     Identification No.)
**1710 Route Transcanadienne, Dorval, Quebec, Canada, H9P 1H7**
(Address of principal executive offices)
**(514) 685-2180**
(Registrant's telephone number, including Area Code)

(Former name, former address and former fiscal year, 

if changed since last report)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
****
Yes	**X**		No    _____

Indicate the number of shares outstanding of each of the Issuer's classes of common equity, as of August 14, 2003: 2,752,254.
** 
**GRAND TOYS INTERNATIONAL, INC.
 
Index to Quarterly Report on Form 10 - Q
Filed with the Securities and Exchange Commission**Period ended June 30, 2003
 **ITEMS IN FORM 10 - Q**PAGE**Part I - Financial Information

Item 1.  Consolidated Financial Statements:  
Consolidated Balance Sheets 
At June 30, 2003 and December 31, 2002   
Consolidated Statements of Operations 
For the three Month and Six Month Periods ended June 30, 2003 and 2002   
Consolidated Statements of Stockholders' Equity and Comprehensive Income  
For the Six Month Period ended June 30, 2003    
Consolidated Statements of Cash Flows 
For the Six Month Period ended June 30, 2003 and 2002   
Notes to Consolidated Financial Statements   
Item 2.  Management's Discussion and Analysis of Financial Condition 
and  Results of Operations 
Item 3. Quantitative and Qualitative Disclosures About Market Risks 
Item 4.  Controls and Procedures **Part II - Other Information   
Item 1.  Legal proceedings 
Item 2.  Changes in Securities and Use of Proceeds 
Item 3.  Defaults Upon Senior Securities 
Item 4.  Submission of Matters to a Vote of Security Holders 
Item 5.  Other Information 
Item 6.  Exhibits and Reports on Form 8-K  
Signatures   
Certifications ******************
#### Higginbotham, executrix, *v.*Anderson *et al.*

No. 8527.

March 3, 1932.

Rehearing denied March 5, 1932.

*E. H. George,*for plaintiff.

*Miles W. Lewis*and *Charles W. Baldwin,*for defendants.

Per Curiam.

This case coining on for decision by the entire bench of six Justices, and the court standing evenly divided, Russell, C. J., and Hill and Hines, JJ., being of the opinion that the judgment of the trial court should be affirmed, and Beck, P. J., and Atkinson and Gilbert, JJ., being of the opinion that the judgment should be reversed, the judgment stands affirmed by operation of law.

Russell, C. J.,

being of the opinion, as stated in case No. 8526, ante, that the petition did not set forth a cause of action and should have been dismissed upon demurrer, and that consequently the further proceedings of the trial succeeding the ruling upon demurrer were nugatory, it naturally follows that I am of the opinion that the court had no right to amend the judgment in any respect, and therefore that he did not err in refusing to allow the attorney’s fees.
Editorial Note on Part 509
Editorial Note: Nomenclature changes to part appear at 88 FR 45066, July 14, 2023.

§ 509.7 Unavoidability. ( a ) Tolerances and action levels in this part are established at levels based on the unavoidability of the poisonous or deleterious substance concerned and do not establish a permissible level of contamination where it is avoidable.
( b ) Compliance with tolerances, regulatory limits, and action levels does not excuse failure to observe either the requirement in section 402(a)(4) of the act that food may not be prepared, packed, or held under insanitary conditions or the other requirements in this chapter that food manufacturers must observe current good manufacturing practices. Evidence obtained through factory inspection or otherwise indicating such a violation renders the food unlawful, even though the amounts of poisonous or deleterious substances are lower than the currently established tolerances, regulatory limits, or action levels. The manufacturer of food must at all times utilize quality control procedures which will reduce contamination to the lowest level currently feasible.
[42 FR 52821, Sept. 30, 1977, as amended at 55 FR 20786, May 21, 1990]
§ 582.1235 Caramel. ( a ) *Product.* Caramel.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
# C_2014388EN.01003101.xml

| 3.11.2014 | EN | Official Journal of the European Union | C 388/31 |
| --- | --- | --- | --- |

3.11.2014

EN

Official Journal of the European Union

C 388/31

---

Action brought on 7 August 2014 — ZZ and Others v EEAS

(Case F-78/14)

2014/C 388/39

Language of the case: French

Parties

Parties

Applicants: ZZ and Others (represented by: Dario de Abreu Caldas, Micael de Abreu Caldas and Jean-Noël Louis, lawyers)

Applicants:

Defendant: European External Action Service (EEAS)

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

Annulment of the decisions not to promote the applicants to the next grade in the 2013 promotion procedure of the European External Action Service (EEAS)

Form of order sought

Form of order sought

The applicants claim that the Tribunal should:

| — | annul the decisions of 9 and 14 October 2013 establishing the list of officials promoted under the 2013 promotion procedure, |
| --- | --- |

—

annul the decisions of 9 and 14 October 2013 establishing the list of officials promoted under the 2013 promotion procedure,

| — | order the EEAS to pay the costs. |
| --- | --- |

—

order the EEAS to pay the costs.

---
EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CEC Entertainment, Inc. (the Company) on Form 10-Q for the quarter ended July 2, 2006 as
filed with the Securities and Exchange Commission on the date hereof (the Report), the undersigned certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



/s/ Richard M. FrankRichard M. FrankChief Executive OfficerApril 23, 2007


A signed original of this written statement required by Section 906 has been provided to CEC
Entertainment, Inc. and will be retained by CEC Entertainment, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.



29
§ 861.38 Standards advisory committees. ( a ) The Food and Drug Administration will establish advisory committees to which proposed regulations may be referred, and these committees shall consider such referrals in accordance with this section and part 14 of this chapter. Such advisory committees, which may not be classification panels, shall be considered ad hoc advisory committees. Their members shall be selected in accordance with §§ 14.82 and 14.84, except that no member may be a regular full-time FDA employee. Each advisory committee established under this section shall include as nonvoting members a representative of consumer interests and a representative of interests of the device manufacturing industry.
( b ) A proposed regulation to establish, amend, or revoke a performance standard shall be referred to an advisory committee for a report and recommendation with respect to any matter involved in the proposed regulation which requires the exercise of scientific judgment if: ( 1 ) The Food and Drug Administration determines that such referral is necessary or appropriate under the circumstances; or
( 2 ) Requested by an interested person, in the form of a citizen petition in accordance with § 10.30 of this chapter, which is made within the period provided for comment on the proposed regulation and which demonstrates good cause for referral.
( c ) When a proposed regulation is referred to an advisory committee, the Food and Drug Administration will furnish the committee with the data and information upon which the proposed regulation is based. After independently reviewing the materials furnished by the Food and Drug Administration and any other available data and information, the advisory committee shall, within 60 days of the referral, submit a report and recommendation on the proposed regulation, together with all underlying data and information and a statement of the reason or basis for the recommendation. A copy of the report and recommendation will be publicly displayed in the office of the Dockets Management Staff, Food and Drug Administration.
( d ) Where appropriate, each proposed regulation establishing a standard published in the Federal Register will include a call for nominations to the advisory committee for that particular standard.
[45 FR 7484, Feb. 1, 1980, as amended at 57 FR 58405, Dec. 10, 1992; 88 FR 45067, July 14, 2023]